Skip to main content
Top
Published in: Clinical Rheumatology 4/2007

01-04-2007 | Original Article

Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors

Authors: Leonel Daza, Martin Aguirre, Martin Jimenez, Rafael Herrera, J. J. Bollain

Published in: Clinical Rheumatology | Issue 4/2007

Login to get access

Abstract

High atherosclerosis prevalence was found in rheumatoid arthritis (RA), and the von Willebrand factor (vWF) was shown to be a marker for endothelial damage. The aim of this study was to evaluate the association of intima-media thickness of the left common carotid artery with vWF serum levels in rheumatoid arthritis patients without cardiovascular risk factors. We included 55 RA female patients, each with at least 5 years of duration of the disease, and 20 healthy female subjects as members of the control group. The vWF, cholesterol, triglycerides, and the immune variables—rheumatoid factor and reactive C protein—were evaluated. The media thickness and intima-media thickness (IMT) in patients and in the control subjects were assessed by Doppler ultrasound of the left common carotid artery. Although the ages for RA patients and healthy female controls were not different, the IMT of the left common carotid artery (IMT CCA) in rheumatoid arthritis patients was increased in comparison with healthy control measurements, the mean being 0.67 mm (SD 0.18) vs 0.58 mm (SD 0.10) with a p value 0.01. The vWF serum levels showed differences in RA patients from those in control patients, 145.6 (SD 30.08) vs 121.8 (SD 37.17), respectively, with p=0.007. A correlation was also found between vWF with IMT CCA in the RA patients: r=0.390 and p<0.05. We concluded that the measurements of the left common carotid artery intima-media thickness together with the von Willebrand factor serum levels could give valuable information about the artery status and the atherosclerosis process in early stages in patients with rheumatoid arthritis without cardiovascular risk factors.
Literature
1.
go back to reference Wiles N, Symmons DP, Harrison B, Barret E, Barret JH, Scott DG, Silman AJ (1999) Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum 42:1339–1346PubMedCrossRef Wiles N, Symmons DP, Harrison B, Barret E, Barret JH, Scott DG, Silman AJ (1999) Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum 42:1339–1346PubMedCrossRef
2.
go back to reference Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Kleinheksel SM, Cathey MA (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMedCrossRef Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Kleinheksel SM, Cathey MA (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMedCrossRef
3.
go back to reference Pap T, Distler O (2005) Linking angiogenesis to bone destruction in arthritis. Arthritis Rheum 52:1346–1348PubMedCrossRef Pap T, Distler O (2005) Linking angiogenesis to bone destruction in arthritis. Arthritis Rheum 52:1346–1348PubMedCrossRef
4.
5.
go back to reference Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J (2003) Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis. Clin Exp Rheumatol 21:63–69PubMed Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J (2003) Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis. Clin Exp Rheumatol 21:63–69PubMed
6.
go back to reference Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201PubMedCrossRef Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201PubMedCrossRef
7.
go back to reference Felmeden DC, Blann AD, Spencer CG, Beevers DG, Lip GY (2003) A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul Fibrinolysis 14:425–431PubMedCrossRef Felmeden DC, Blann AD, Spencer CG, Beevers DG, Lip GY (2003) A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul Fibrinolysis 14:425–431PubMedCrossRef
8.
go back to reference Voskuyl AE, Hazes JM, Zwinderman AH, Paleolog EM, van der Meer FJ, Daha MR et al (2003) Diagnostic strategy for the assessment of rheumatoid vasculitis. Ann Rheum Dis 62:407–413PubMedCrossRef Voskuyl AE, Hazes JM, Zwinderman AH, Paleolog EM, van der Meer FJ, Daha MR et al (2003) Diagnostic strategy for the assessment of rheumatoid vasculitis. Ann Rheum Dis 62:407–413PubMedCrossRef
9.
go back to reference Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Isomäki H (1995) Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 22:1065–1067PubMed Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Isomäki H (1995) Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 22:1065–1067PubMed
10.
go back to reference van Doornum S, Mc Coll G, Wicks IP (2002) Accelerated atherosclerosis: an extra-articular feature of rheumatoid arthritis? Arthritis Rheum 46:862–873PubMedCrossRef van Doornum S, Mc Coll G, Wicks IP (2002) Accelerated atherosclerosis: an extra-articular feature of rheumatoid arthritis? Arthritis Rheum 46:862–873PubMedCrossRef
11.
go back to reference Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA (2003) Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine 82:407–413PubMedCrossRef Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA (2003) Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine 82:407–413PubMedCrossRef
12.
go back to reference Del Rincón I, Williams K, Stern M, Freeman GL, Escalante A (2001) High Incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745CrossRef Del Rincón I, Williams K, Stern M, Freeman GL, Escalante A (2001) High Incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745CrossRef
13.
go back to reference Park YB, Ahn Ch-W, Choi H, Lee SH, In B-H, Lee H-Ch et al (2002) Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 46:1714–1719PubMedCrossRef Park YB, Ahn Ch-W, Choi H, Lee SH, In B-H, Lee H-Ch et al (2002) Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 46:1714–1719PubMedCrossRef
14.
go back to reference Del Rincon I, Williams K, Stern MP, Freeman GL, O’leary D, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48:1833–1840PubMedCrossRef Del Rincon I, Williams K, Stern MP, Freeman GL, O’leary D, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48:1833–1840PubMedCrossRef
15.
go back to reference Jonsson SW, Backman Ch, Johnson O, Karp O, Lundströn E, Sundqvist KG, Dahlqvist SR (2001) Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 28:2597–2602PubMed Jonsson SW, Backman Ch, Johnson O, Karp O, Lundströn E, Sundqvist KG, Dahlqvist SR (2001) Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 28:2597–2602PubMed
16.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
17.
go back to reference Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joints counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joints counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef
18.
go back to reference Rosvall M, Ostergren PO, Hedblad B, Isacsson S-O, Janzon L, Berglund G (2000) Occupational status, educational level, and the prevalence of carotid atherosclerosis in a general population sample of middle-aged Swedish men and women: results from the Malmö diet and cancer study. Am J Epidemiol 152:334–346PubMedCrossRef Rosvall M, Ostergren PO, Hedblad B, Isacsson S-O, Janzon L, Berglund G (2000) Occupational status, educational level, and the prevalence of carotid atherosclerosis in a general population sample of middle-aged Swedish men and women: results from the Malmö diet and cancer study. Am J Epidemiol 152:334–346PubMedCrossRef
19.
go back to reference Sramek A, Bosch J, Reiber J, van OOstayen J, Rosendaal F (2000) Ultrasound assessment of atherosclerotic vessel wall changes: Reproductibility of intima-media thickness measurements in carotid and femoral arteries. Invest Radiol 35:699–706PubMedCrossRef Sramek A, Bosch J, Reiber J, van OOstayen J, Rosendaal F (2000) Ultrasound assessment of atherosclerotic vessel wall changes: Reproductibility of intima-media thickness measurements in carotid and femoral arteries. Invest Radiol 35:699–706PubMedCrossRef
20.
go back to reference Roman M, Moeller E, Davis AB, Paget S, Crow M, Lockshin M et al (2006) Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 144:249–256PubMed Roman M, Moeller E, Davis AB, Paget S, Crow M, Lockshin M et al (2006) Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 144:249–256PubMed
21.
go back to reference Grover S, Sinha RP, Singh U, Tewari S, Aggarwal A, Misra R (2006) Subclinical atherosclerosis in Rheumatoid Arthritis in India. J Rheumatol 33:244–247PubMed Grover S, Sinha RP, Singh U, Tewari S, Aggarwal A, Misra R (2006) Subclinical atherosclerosis in Rheumatoid Arthritis in India. J Rheumatol 33:244–247PubMed
22.
go back to reference Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S (2002) Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29:875–882PubMed Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S (2002) Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29:875–882PubMed
23.
go back to reference Wallberg-Jonsson S, Cederfelt M, Rantapaa Dahlqvist S (2000) Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8-year follow-up study. J Rheumatol 27:71–75PubMed Wallberg-Jonsson S, Cederfelt M, Rantapaa Dahlqvist S (2000) Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8-year follow-up study. J Rheumatol 27:71–75PubMed
24.
go back to reference McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD (2001) Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 40:640–644PubMedCrossRef McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD (2001) Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 40:640–644PubMedCrossRef
25.
go back to reference Hoekstra M, Haagsma CJ, Doelman CJ, van der Laar MA (2005) Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis 64:141–143PubMedCrossRef Hoekstra M, Haagsma CJ, Doelman CJ, van der Laar MA (2005) Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis 64:141–143PubMedCrossRef
26.
go back to reference Cisternas M, Gutierrez M, Klaassen J, Acosta A, Jacobelli S (2002) Cardiovascular risk factors in Chilean patients with rheumatoid arthritis. J Rheumatol 29:1619–1622PubMed Cisternas M, Gutierrez M, Klaassen J, Acosta A, Jacobelli S (2002) Cardiovascular risk factors in Chilean patients with rheumatoid arthritis. J Rheumatol 29:1619–1622PubMed
27.
go back to reference Ruderman EM, Crawford JM, Maier A, Liu JJ, Gravallese EM, Weinblat ME (1997) Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. Br J Rheumatol 36:210–213PubMedCrossRef Ruderman EM, Crawford JM, Maier A, Liu JJ, Gravallese EM, Weinblat ME (1997) Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. Br J Rheumatol 36:210–213PubMedCrossRef
28.
go back to reference Abraham S, Begur S, Isenberg D (2004) Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 63:123–129PubMedCrossRef Abraham S, Begur S, Isenberg D (2004) Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 63:123–129PubMedCrossRef
29.
go back to reference Iannello S, Cavaleri A, Milazzo P, Cantarella S, Belfiore F (2003) Low fasting serum triglyceride level as a precocious marker of autoimmune disorders. MedGenMed 5(3):20PubMed Iannello S, Cavaleri A, Milazzo P, Cantarella S, Belfiore F (2003) Low fasting serum triglyceride level as a precocious marker of autoimmune disorders. MedGenMed 5(3):20PubMed
30.
go back to reference Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Haffner SM (2005) Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54:3140–3147PubMed Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Haffner SM (2005) Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54:3140–3147PubMed
Metadata
Title
Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors
Authors
Leonel Daza
Martin Aguirre
Martin Jimenez
Rafael Herrera
J. J. Bollain
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0338-7

Other articles of this Issue 4/2007

Clinical Rheumatology 4/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine